Starpharma signs DEP® ADC Research Agreement with MSD
On February 11, 2021, Starpharma (OTCQX: SPHRY) announced a Research Agreement with MSD to evaluate dendrimer-based Antibody Drug Conjugates (ADCs) using their proprietary DEP® technology.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
On February 11, 2021, Starpharma (OTCQX: SPHRY) announced a Research Agreement with MSD to evaluate dendrimer-based Antibody Drug Conjugates (ADCs) using their proprietary DEP® technology. This collaboration aims to enhance ADC characteristics, building on Starpharma's successful preclinical studies, including their DEP® HER-2 ADC, which demonstrated significant tumor regression and 100% survival in models. Starpharma already has four clinical-stage oncology products developed from the DEP® technology, one of which is in partnership with AstraZeneca.
Positive
- Research Agreement with MSD enhances Starpharma's ADC development potential.
- Future studies will leverage DEP® technology's advantages over conventional ADCs.
- Previous preclinical studies showed promising results, including 100% survival rates.
Negative
- None.
Details
News Market Reaction – SPHRY
The recorded move for SPHRY in the trading session of this news was +13.76%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MELBOURNE, Australia, Feb. 11, 2021 /PRNewswire/ -- Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that is has signed a Research Agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth NJ USA. Under the agreement, MSD will conduct a preclinical research evaluation of dendrimer based Antibody Drug Conjugates (ADCs) utilising Starpharma's proprietary DEP® technology.
Dr Jackie Fairley, CEO of Starpharma commented: "MSD is a recognised leader in oncology, and we are delighted to have signed this new Research Agreement in such an innovative and valuable area."
DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs including greater homogeneity, site specific attachment, and higher drug antibody ratio (DAR), than conventional ADC approaches. DEP® ADCs are the subject of internal and partnered programs.
Starpharma has previously demonstrated the significant advantages conveyed by DEP® ADCs in multiple preclinical studies, including its DEP® HER-2 ADC, which showed significant tumour regression and
Media: Sumit Media Grant Titmus Mob: +61 419 388 161 | Starpharma Holdings Limited Dr Jackie Fairley, Chief Executive Officer Nigel Baade, CFO and Company Secretary investor.relations@starpharma.com 4-6 Southampton Crescent Abbotsford Vic 3067 | Disclosure
|
View original content:http://www.prnewswire.com/news-releases/starpharma-signs-dep-adc-research-agreement-with-msd-301227420.html
SOURCE Starpharma
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.